The drug has been characterised biochemically and its mode of action has been determined. It is composed of a set of peptides that act to stimulate the releases and regulation of a molecular cascade that modulates the Hypothalamo-Pituitary-Adrenal (HPA) axis. In addition, Aimspro has powerful anti-inflammatory properties as it contains cytokines that induce a predominantly TH-2 anti-inflammatory profile in the patient.

It has become apparent that some of the peptides in Aimspro are regulated and bound by specific carrier molecules that may regulate the action and release of their ligand and are probably necessary for the appropriate regulation and pharmacokinetics of the molecular machinery. The carrier molecules also function as a slow release mechanism, releasing bioactive components over several days."

It is a highly specific product obtained by vaccinating a specially selected herd of goats and then preparing the active component.

This is a powerful anti-inflammatory agent which is associated with the induction of tissue repair factors some of which are known to enhance nerve conduction.

Aimspro has been designated Orphan Status in the USA and Australia for the treatment of ALS and Orphan Status in Australia for Krabbes.

Like a few dramatic developments in the pharmaceutical world the creation of Aimspro was an offshoot of a line of research looking for a treatment / cure for a specific human affliction. Since World War 2 people have been increasingly protected against many diseases by means of inoculations that involve the use of vaccines. Some that spring to mind include polio (Salk), hepatitis, meningitis, cervical cancer, smallpox, tetanus, rabies, influenza and many others. If one takes polio as an example, the Salk vaccine is produced by injecting dead polio viruses into fertilized hen’s eggs and then extracting the created antibodies produced by the embryo to counter this ‘invasion’. The antibodies are then stored as a serum in vials before injection into humans.

The antibodies are officially described as “polyclonal antibodies”. They are not chemical drugs; they are classified as “biopharmaceuticals”.

Side effects may occur:

Irritation at injection site.

Multiple Sclerosis people who have initially shown a clinically satisfactory response to AIMSPRO go on to describe periods of marked diminution of effect, to the extent that they suspect an MS relapse has occurred. How should this be dealt with? It is important, first of all, to check whether any new medication has been commenced in recent days.

For example, highly important physiologically acting drugs, such as the anti-epileptic agent LAMOTRIGINE and the cardiac medication FLECAINIDE, will almost certainly antagonise the actions of AIMSPRO, so if either of these two licensed medications is indicated for medial reasons, then the administration of AIMSPRO should be temporarily suspended, rather than the other way around. Your doctor will explain this reasoning.

If the deterioration cannot be accounted for by the recent introduction of an antagonistic medication, then a careful search must be undertaken for a hidden focus of infection. This might come in the form of a urinary tract or pulmonary infection and I have seen this happen with both bacterial and viral causative agents. Even dental abscesses and minor wound infections can have the same effect.

It is very likely that the anti-inflammatory activity of AIMSPRO is diverted to these sites of active pathology. First, the infection must be treated effectively and your doctor will be the guide to what is required to achieve this. Next, the question will arise as to whether AIMSPRO should be discontinued for a time while the infection is dealt with.

This is also something to discuss with your doctor, but there is logic to that approach, certainly given the cost of the medication. Many patients find that attention to these matters results in a renewed palliative effect when AIMSPRO is re-commenced a few weeks later".

A patent for 'The Treatment of HIV' has been added to the AIMSPRO IP portfolio, having an effective date of 31st March 2009. The patent has been granted by the African Intellectual Property Organisation (O.A.P.I. – Organisation Africaine de la Propriété Intellectuelle) and it covers the African states of Benin, Burkina Faso, Cameroon, Central African Republic, Chad, Republic of Congo, Cote d'Ivoire, Equatorial Guinea, Gabon, Guinea, Guinea Bissau, Mali, Mauritania, Niger, Senegal and Togo. The grant of this single patent is valid in all these countries. Daval International

Note.

There are very important mandatory import formalities for biological products throughout the world, though the fact that a hyper immune serum is derived from a low risk country helps facilitate the necessary application process.

Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis has been designated to Aimspro® by the TGA and the FDA. ALS is the most common form of Motor Neuron Disease (MND), also known as Lou Gehrig’s disease.

Review Paper - www.sciencedirect.com/science

Orphan Status for the treatment of ‘Krabbes Disease’ has been designated to Aimspro® by the TGA

Aimspro® has marketing authorisation designated by the MHRA (UK) therefore is available as a ‘special’

Aimspro® has category B status designated by the TGA

Note.

Drugs / medication that have been designated an Orphan Status or Special Licence can be prescribed by a doctor, neurologist, dentist, and many drugs that have been licensed for a specific disease / disorder are prescribed off label, in other word used to treat another disease they have not been licensed for, it is not uncommon!

Top of Page

Other Web Sites

Review Paper - www.sciencedirect.com/science

Aimspro®